作者
Nagy Mekhail,Robert M. Levy,Timothy R. Deer,Leonardo Kapural,Sean Li,Kasra Amirdelfan,Corey Hunter,Steven M. Rosen,Shrif Costandi,Steven Falowski,Abram H. Burgher,Jason E. Pope,Christopher Gilmore,Farooq Qureshi,Peter S. Staats,James Scowcroft,Tory McJunkin,Christopher K. Kim,Michael Yang,Thomas Stauss,Richard Rauck,Rui Duarte,Nicole Soliday,Angela Leitner,Erin Hanson,Zhonghua Ouyang,Dave Mugan,Lawrence Poree
摘要
A novel, spinal cord stimulation (SCS) system with a physiologic closed-loop (CL) feedback mechanism controlled by evoked compound action potentials (ECAPs) enables the optimization of physiologic neural dose and the accuracy of the stimulation, not possible with any other commercially available SCS systems. The report of objective spinal cord measurements is essential to increase the transparency and reproducibility of SCS therapy. Here, we report a cohort of the EVOKE double-blind randomized controlled trial treated with CL-SCS for 36 months to evaluate the ECAP dose and accuracy that sustained the durability of clinical improvements.